Answers are grounded in this paper and cite their sources.
Monoclonal antibodies (mAbs) against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) reduced Coronavirus Disease 2019 (COVID-19) hospitalizations in people at risk of clinical worsening. Real-world descriptions are limited.
No takes yet. Share an insight, caveat, or question.
Soria et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: